These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15736891)

  • 1. Periodontal disease as part of the insulin resistance syndrome in diabetic patients.
    Nishimura F; Soga Y; Iwamoto Y; Kudo C; Murayama Y
    J Int Acad Periodontol; 2005 Jan; 7(1):16-20. PubMed ID: 15736891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome, diabetes and cardiovascular events: current controversies and recommendations.
    Zarich SW
    Minerva Cardioangiol; 2006 Apr; 54(2):195-214. PubMed ID: 16778752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of selected markers of inflammation in patients with clinical symptoms of insulin resistance and normal renal function].
    Bogdański P; Pupek-Musialik D; Luczak M; Szulińska M
    Pol Merkur Lekarski; 2006 Aug; 21(122):165-8; discussion 169. PubMed ID: 17144103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effects of chronic inflammatory periodontal disease on diabetes mellitus.
    Nishimura F; Kono T; Fujimoto C; Iwamoto Y; Murayama Y
    J Int Acad Periodontol; 2000 Apr; 2(2):49-55. PubMed ID: 12666961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study.
    Hanley AJ; Karter AJ; Williams K; Festa A; D'Agostino RB; Wagenknecht LE; Haffner SM
    Circulation; 2005 Dec; 112(24):3713-21. PubMed ID: 16344402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gestational diabetes, pregnancy hypertension, and late vascular disease.
    Carpenter MW
    Diabetes Care; 2007 Jul; 30 Suppl 2():S246-50. PubMed ID: 17596480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
    Schernthaner GH; Schernthaner G
    Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
    Grundy SM
    J Am Coll Cardiol; 2006 Mar; 47(6):1093-100. PubMed ID: 16545636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and NASH.
    Marchesini G; Marzocchi R
    Clin Liver Dis; 2007 Feb; 11(1):105-17, ix. PubMed ID: 17544974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of inflammatory cytokines in diabetes and its complications.
    King GL
    J Periodontol; 2008 Aug; 79(8 Suppl):1527-34. PubMed ID: 18673007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus.
    Mojiminiyi OA; Abdella NA
    Scand J Clin Lab Invest; 2007; 67(2):215-25. PubMed ID: 17366001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Components of metabolic syndrome predicting diabetes: no role of inflammation or dyslipidemia.
    Norberg M; Stenlund H; Lindahl B; Andersson C; Weinehall L; Hallmans G; Eriksson JW
    Obesity (Silver Spring); 2007 Jul; 15(7):1875-85. PubMed ID: 17636107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and the metabolic syndrome as predictors of cardiovascular risk: where are we now?
    Sattar N
    Minerva Endocrinol; 2005 Sep; 30(3):121-38. PubMed ID: 16208304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes?
    Joffe D; Yanagisawa RT
    Med Clin North Am; 2007 Nov; 91(6):1107-23, ix. PubMed ID: 17964912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ; Delgado-Osorio H
    Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.